A phase II study evaluating a maintenance strategy of Gleevce (imatinib mesylate) and bevacizumab in patients with advanced, non-squamous, non-small cell lung cancer, following completion of first-line chemotherapy with bevacizumab
Phase of Trial: Phase II
Latest Information Update: 03 May 2013
At a glance
- Drugs Bevacizumab (Primary) ; Imatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 May 2013 Additional lead tral centre added as reported by ClinicalTrials.gov.
- 16 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Oct 2008 Planned end date changed from 1 Nov 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.